{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:39:38Z","timestamp":1793176778629,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007560","name":"Chiesi Pharmaceuticals SpA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jacl.2026.07.028","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:20:11Z","timestamp":1785424811000},"page":"2148-2159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term treatment of homozygous familial hypercholesterolemia with lomitapide: 11 years of safety and effectiveness findings from the Lomitapide Observational Worldwide Evaluation Registry"],"prefix":"10.1016","volume":"20","author":[{"given":"Dirk J.","family":"Blom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Larrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Makris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Underberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sallyann","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2026.07.028_bib1","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance","volume":"44","author":"Cuchel","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.07.028_bib2","first-page":"147","article-title":"Genetic screening for homozygous and heterozygous familial hypercholesterolemia","volume":"3","author":"Izar","year":"2010","journal-title":"Appl Clin Genet"},{"key":"10.1016\/j.jacl.2026.07.028_bib3","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s12325-021-01720-y","article-title":"Homozygous familial hypercholesterolemia (HoFH) in Saudi Arabia and two cases of lomitapide use in a real-world setting","volume":"38","author":"Mahzari","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.jacl.2026.07.028_bib4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cjco.2020.01.003","article-title":"Familial hypercholesterolemia and the founder effect among Franco-Americans: a brief history and call to action","volume":"2","author":"Mszar","year":"2020","journal-title":"CJC Open"},{"key":"10.1016\/j.jacl.2026.07.028_bib5","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.07.028_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41569-018-0052-6","article-title":"The complex molecular genetics of familial hypercholesterolaemia","volume":"16","author":"Berberich","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacl.2026.07.028_bib7","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/mgg3.203","article-title":"Variable expressivity and co-occurrence of LDLR and LDLRAP1 mutations in familial hypercholesterolemia: failure of the dominant and recessive dichotomy","volume":"4","author":"Fahed","year":"2016","journal-title":"Mol Genet Genomic Med"},{"key":"10.1016\/j.jacl.2026.07.028_bib8","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/eurheartj\/ehx317","article-title":"Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol","volume":"39","author":"Thompson","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.07.028_bib9","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","article-title":"Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy","volume":"124","author":"Raal","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.07.028_bib10","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jacl.2015.11.011","article-title":"LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: rationale and design","volume":"10","author":"Blom","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.07.028_bib11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2026.07.028_bib12","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1161\/CIRCULATIONAHA.117.028208","article-title":"Long-term efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in patients with homozygous familial hypercholesterolemia","volume":"136","author":"Blom","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.07.028_bib13","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia","volume":"356","author":"Cuchel","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2026.07.028_bib14","doi-asserted-by":"crossref","first-page":"402","DOI":"10.5551\/jat.38216","article-title":"Efficacy and safety of lomitapide in Japanese patients with homozygous familial hypercholesterolemia","volume":"24","author":"Harada-Shiba","year":"2017","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jacl.2026.07.028_bib15","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jacl.2020.08.006","article-title":"Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER)","volume":"14","author":"Underberg","year":"2020","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.07.028_bib16","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jacl.2016.03.088","article-title":"Long-term efficacy and safety of lomitapide for the treatment of homozygous familial hypercholesterolemia: results of the phase 3 extension trial","volume":"10","author":"Blom","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.07.028_bib17","unstructured":"European Medicines Agency. Lojuxta summary of product characteristics. 2026. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lojuxta-epar-product-information_en.pdf. Accessed June 2026."},{"key":"10.1016\/j.jacl.2026.07.028_bib18","unstructured":"US Food and Drug Administration. JUXTAPID\u00ae (lomitapide) product information. 2026. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/203858s027lbl.pdf. Accessed June 2026."},{"key":"10.1016\/j.jacl.2026.07.028_bib19","unstructured":"US Food and Drug Administration. FaD. Repatha\u00ae (evolocumab) product information. 2021. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125522s29s31lbl.pdf. Accessed March 2026."},{"key":"10.1016\/j.jacl.2026.07.028_bib20","unstructured":"Food and Drug Administration. Praluent\u00ae (alirocumab) product information. 2017. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125559s002lbl.pdf. Accessed March 2026."},{"key":"10.1016\/j.jacl.2026.07.028_bib21","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jacl.2026.01.011","article-title":"Update on familial hypercholesterolemia: an expert clinical consensus from the National Lipid Association","volume":"20","author":"Ahmad","year":"2026","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.07.028_bib22","doi-asserted-by":"crossref","first-page":"e647","DOI":"10.1016\/j.jacl.2024.08.013","article-title":"Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: an expert clinical consensus from the National Lipid Association","volume":"18","author":"Soffer","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.07.028_bib23","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12872-024-03949-1","article-title":"Relationship between serum apolipoprotein B and risk of all-cause and cardiovascular disease mortality in individuals with hypertension: a prospective cohort study","volume":"24","author":"Huang","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jacl.2026.07.028_bib24","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0140-6736(08)61076-4","article-title":"Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study","volume":"372","author":"McQueen","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2026.07.028_bib25","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1093\/eurheartj\/ehag382","article-title":"Familial hypercholesterolaemia in children and adolescents: a European Atherosclerosis Society consensus statement","volume":"47","author":"Wiegman","year":"2026","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.07.028_bib26","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s12325-017-0531-x","article-title":"Efficacy of lomitapide in the treatment of familial homozygous hypercholesterolemia: results of a real-world clinical experience in Italy","volume":"34","author":"D'Erasmo","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.jacl.2026.07.028_bib27","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/eurjpc\/zwab229","article-title":"Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study","volume":"29","author":"D'Erasmo","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2026.07.028_bib28","doi-asserted-by":"crossref","first-page":"203","DOI":"10.5551\/jat.LE003","article-title":"Gradual dose titration of lomitapide may prevent therapeutic delays in patients with homozygous familial hypercholesterolemia","volume":"30","author":"Harada-Shiba","year":"2023","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jacl.2026.07.028_bib29","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/liv.15497","article-title":"Long-term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia","volume":"43","author":"Larrey","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.jacl.2026.07.028_bib30","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S2213-8587(24)00233-X","article-title":"Lomitapide for the treatment of paediatric patients with homozygous familial hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 study","volume":"12","author":"Masana","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacl.2026.07.028_bib31","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.07.028_bib32","first-page":"S93","article-title":"Real-world LDL-C changes experienced with lomitapide modelled to potentially increase life-expectancy in homozygous familial hypercholesterolemia (HoFH)","volume":"21","author":"Ager","year":"2018","journal-title":"Value\u00a0Health"},{"key":"10.1016\/j.jacl.2026.07.028_bib33","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1177\/2047487317730473","article-title":"The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: a modelling analysis","volume":"24","author":"Leipold","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2026.07.028_bib34","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13023-018-0841-3","article-title":"Target achievement and cardiovascular event rates with lomitapide in homozygous Familial Hypercholesterolaemia","volume":"13","author":"Blom","year":"2018","journal-title":"Orphanet J\u00a0Rare Dis"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426004575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426004575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:27:26Z","timestamp":1793176046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426004575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1933287426004575"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.07.028","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term treatment of homozygous familial hypercholesterolemia with lomitapide: 11 years of safety and effectiveness findings from the Lomitapide Observational Worldwide Evaluation Registry","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.07.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}